August 22, 2025

Linear Hyperpigmentation After Chemotherapy: What's Your Diagnosis?

A 15-year-old girl developed distinctive, painless, whip-like streaks across her trunk and back after receiving combination chemotherapy for ovarian yolk sac tumor. What’s your diagnosis?

Conexiant

August 19, 2025

‘Enough Is Enough’—But When?

How Bogalusa, Louisiana became a lens on the US gun violence epidemic—where race, poverty, policy, and profit converge and communities bear the cost.

KFF Health News

August 15, 2025

Approved: HPV-Targeted Immunotherapy for Recurrent Respiratory Papillomatosis

Standard management has relied on repeated surgical debulking, which does not eradicate underlying HPV infection.

Conexiant

August 15, 2025

COVID-19 Booster in Pregnancy Linked to Higher Infant Antibodies

A COVID-19 mRNA booster given during pregnancy is associated with greater transplacental antibody transfer and sustained infant antibody levels through 6 months of age.

Conexiant

August 14, 2025

Who Benefits From Vaccine Misinformation?

US vaccination rates have declined in recent years, coinciding with increased public debate over vaccine safety and policy.

KFF Health News

August 12, 2025

FDA Approves First Therapy for Non-cystic Fibrosis Bronchiectasis

Brensocatib (Brinsupri) will offer a new treatment option for patients 12 years and older.

Conexiant

August 12, 2025

Advanced-Practice Providers Filling Rural ER Gaps

Rural emergency rooms across the U.S. are increasingly staffed by physician assistants and nurse practitioners instead of physicians, raising debates over care quality, staffing shortages, and access to emergency services.

KFF Health News

August 07, 2025

Flu Treatment Linked to Lower Neuropsychiatric Risk in Pediatric and Adolescent Patients

Subgroup analyses demonstrated a greater reduction in neurologic events than psychiatric events, though the reduction in psychiatric events was not statistically significant.

Conexiant

August 06, 2025

New COVID Booster Matches Efficacy, Raises Antibodies

A phase 3 randomized trial found that Moderna’s next-generation COVID-19 vaccine, mRNA-1283, was non-inferior to the earlier mRNA-1273 vaccine in preventing COVID-19 and produced stronger neutralizing antibody responses.

Conexiant